Personalized Integrated Alcohol and Sexual Assault Prevention Among College Students
Launched by GEORGIA STATE UNIVERSITY · Mar 15, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Aim 1: Test the efficacy of Positive Change (+Change) among college students in each risk group (cisgender heterosexual men; cisgender heterosexual women; LGBTQ). Students aged 18-25 who engage in heavy episodic drinking will be recruited from 2 large public universities (n = 3,300) and will be randomly assigned to +Change, +Change plus +Booster, or an attention control. Alcohol use, sexual assault (victimization and perpetration), and bystander intervention will be assessed at baseline, 3-, 6-, 9-, and 12-month follow-ups.
H1a: +Change conditions (+Change and +Change plus Booster) will re...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18-25 years old
- • Current student at university of study
- • Valid email address at university of study
- • Endorse engaging in heavy episodic drinking at least once in the past month on the screening survey
- Exclusion Criteria:
- • • There are no exclusion criteria other than not meeting inclusion criteria
About Georgia State University
Georgia State University is a leading research institution dedicated to advancing knowledge through innovative clinical trials and studies. With a strong emphasis on public health and community well-being, the university leverages its multidisciplinary expertise to conduct rigorous research aimed at addressing pressing health challenges. As a sponsor of clinical trials, Georgia State University fosters collaboration among researchers, healthcare professionals, and community partners, ensuring ethical standards and scientific integrity are upheld throughout the research process. Its commitment to translating research findings into real-world applications positions the university as a key contributor to the advancement of medical science and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Patients applied
Trial Officials
Amanda Gilmore, PhD
Principal Investigator
Georgia State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials